Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B
- PMID: 1640190
- DOI: 10.1111/j.1365-2796.1992.tb00546.x
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B
Abstract
In Sweden, prophylactic treatment of boys with severe haemophilia has been practised since 1958 in an attempt to convert the disease from a severe to a milder form. The present study population consisted of 60 severe haemophiliacs (52 A, 8 B), aged 3-32 years. Treatment is started when the boys are 1-2 years of age, the regimens used being 24-40 IU F VIII kg-1 three times weekly in haemophilia-A cases (i.e. greater than 2000 IU kg-1 annually) and 25-40 IU F IX kg-1 twice weekly in haemophilia-B cases. The orthopaedic and radiological joint scores (maximum scores of 90 and 78, respectively) are evaluated as recommended by the World Federation of Haemophilia. Of those subjects aged 3-17 years, 29 out of 35 individuals had joint scores of zero. The oldest group had only minor joint defects. The VIII:C and IX:C concentrations had usually not fallen below 1% of normal. All 60 patients are able to lead normal lives. In conclusion, it appears to be possible to prevent haemophilic arthropathy by giving effective continuous prophylaxis from an early age, and preventing the VIII:C or IX:C concentration from falling below 1% of normal.
Comment in
-
Prophylaxis: the next haemophilia treatment.J Intern Med. 1992 Jul;232(1):1-2. doi: 10.1111/j.1365-2796.1992.tb00543.x. J Intern Med. 1992. PMID: 1640188 No abstract available.
Similar articles
-
[Prevention of joint damage in hemophilic children with early prophylaxis].Orthopade. 1999 Apr;28(4):341-6. doi: 10.1007/PL00003616. Orthopade. 1999. PMID: 10335528 Clinical Trial. German.
-
Haemophilia prophylaxis in young patients--a long-term follow-up.J Intern Med. 1997 May;241(5):395-400. doi: 10.1046/j.1365-2796.1997.130135000.x. J Intern Med. 1997. PMID: 9183307
-
When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.Haemophilia. 1998 Jul;4(4):413-7. doi: 10.1046/j.1365-2516.1998.440413.x. Haemophilia. 1998. PMID: 9873763
-
Prophylactic factor replacement in hemophilia.Blood Rev. 2004 Jun;18(2):101-13. doi: 10.1016/S0268-960X(03)00038-9. Blood Rev. 2004. PMID: 15010149 Review.
-
The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.Baillieres Clin Haematol. 1996 Jun;9(2):259-71. doi: 10.1016/s0950-3536(96)80062-x. Baillieres Clin Haematol. 1996. PMID: 8800504 Review.
Cited by
-
Diagnostic evaluation of our patients with hemophilia A: 17-year experience.Turk Pediatri Ars. 2015 Jun 1;50(2):96-101. doi: 10.5152/tpa.2015.2516. eCollection 2015 Jun. Turk Pediatri Ars. 2015. PMID: 26265893 Free PMC article.
-
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.J Thromb Haemost. 2012 Mar;10(3):359-67. doi: 10.1111/j.1538-7836.2011.04611.x. J Thromb Haemost. 2012. PMID: 22212248 Free PMC article. Clinical Trial.
-
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.Vasc Health Risk Manag. 2007;3(4):527-31. Vasc Health Risk Manag. 2007. PMID: 17969383 Free PMC article. Review.
-
State of care for hemophilia in pediatric patients.Paediatr Drugs. 2002;4(3):149-57. doi: 10.2165/00128072-200204030-00002. Paediatr Drugs. 2002. PMID: 11909007 Review.
-
Clinical use of factor VIII and factor IX concentrates.Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s55-63. doi: 10.2450/2013.010s. Blood Transfus. 2013. PMID: 24333314 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical